Curated News
By: NewsRamp Editorial Staff
July 14, 2026
Quantum BioPharma Advances MS Therapy LUCID-MS to Phase 2
TLDR
- Quantum BioPharma's LUCID-MS targets myelin loss directly, potentially offering a first-in-class advantage in MS treatment.
- Phase 1 trials showed safety; FDA IND submitted for Phase 2, with Allucent partnership and specialist engagement planned.
- LUCID-MS aims to restore myelin and improve quality of life for multiple sclerosis patients by targeting neurodegeneration.
- LUCID-MS is a patented molecule shown to reverse myelin degradation in preclinical models, a potential game-changer for MS.
Impact - Why it Matters
This news matters because multiple sclerosis affects millions worldwide, and current treatments primarily manage symptoms or modulate the immune system without directly repairing myelin damage. LUCID-MS aims to restore myelin integrity, potentially slowing or reversing disease progression. If successful in Phase 2 trials, it could offer a groundbreaking therapy that addresses the root cause of MS, improving quality of life for patients. Additionally, Quantum BioPharma's financial strategy with unbuzzd royalties provides a non-dilutive revenue stream, supporting ongoing R&D. For investors, this represents a high-potential opportunity in a biotech firm targeting an unmet medical need, with clear regulatory progress and strategic collaborations.
Summary
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is making significant strides in multiple sclerosis treatment with its proprietary therapy candidate, LUCID-MS. The company recently highlighted in a featured article that Phase 1 clinical studies in healthy volunteers demonstrated a favorable safety profile, with the therapy generally well tolerated. This positive outcome supports advancement into patient-focused studies. In April 2026, Quantum BioPharma submitted an Investigational New Drug application to the U.S. Food and Drug Administration for LUCID-MS, paving the way for a planned Phase 2 clinical trial in people living with multiple sclerosis. The therapy aims to directly address myelin loss and neurodegeneration, potentially offering a first-in-class approach that goes beyond immune modulation. The company is also strengthening operational support through a planned partnership with Allucent and engagement with neurological specialists.
Quantum BioPharma is a biopharmaceutical company focused on innovative treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it leads the development of LUCID-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. The company also invented unbuzzd and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake as of March 31, 2026, and receiving royalty payments of 7% of sales until $250 million is reached, then 3% in perpetuity. Quantum BioPharma retains full rights to develop similar products for pharmaceutical and medical uses. The news was disseminated by InvestorWire, a specialized communications platform within the IBN Dynamic Brand Portfolio, which provides press release syndication and editorial distribution to over 5,000 outlets.
For investors, the latest updates on QNTM are available in the company’s newsroom. This development underscores Quantum BioPharma's commitment to addressing the underlying mechanisms of multiple sclerosis, potentially offering a transformative treatment option for patients. The planned Phase 2 trial and strategic partnerships indicate a robust pipeline and operational focus, making this an important milestone for the company and the MS community.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma Advances MS Therapy LUCID-MS to Phase 2
